Mayo Foundation for Medical Education and Research

Hybritech Incorporated

Other

Donald J Tindall

Mohammad Saeed Saedi

Charles Y Young

George G Klee

Abhay Kumar

Charles Y F Young

Kevin Slawin

Stephen D Mikolajczyk

Robert L Wolfert

Harry G Rittenhouse

Prostate cancer is detected by determining the presence of hK2 RNA in a physiological sample.

Method for detection of micrometastatic prostate cancer

Breast cancer is detected by determining the presence of hK2 polypeptide or hK2 RNA in a physiological sample.

Method for detection of breast cancer

An isolated, substantially homogenous pre-pro, pro or mature hK2 polypeptide is provided as well as biologically active variants or subunits thereof, including a biologically active variant pre-pro hK2 polypeptide having SEQ ID NO:19.

Recombinant hK2 polypeptide

Isolated nucleic acid molecules encoding variant hK2 polypeptides and fragments thereof, as well as expression cassettes and host cells comprising said nucleic acid molecules, are provided. Also provided is a method to express a nucleic acid molecule encoding a variant hK2 polypeptide.

DNA encoding hK2 variant polypeptides

The present invention provides an isolated preparation of monoclonal or polyclonal antibodies which react specifically with human prostate-specific glandular kallikrein (hK2), but which do not cross-react with human prostate-specific antigen (PSA), as well as immunogenic hK2 antigens useful to provide such antibodies.

Growing community of inventors

Rochester, MN, United States of America

Donald J Tindall